A Randomized Trial (Irish Clinical Oncology Research Group 97-01) Comparing Short Versus Protracted Neoadjuvant Hormonal Therapy Before Radiotherapy for Localized Prostate Cancer

• Published in: International journal of radiation oncology, biology, physics Vol. 81; no. 1; pp. 35 - 45
• Main Authors: Armstrong, John G., F.F.R.R.C.S.I, Gillham, Charles M., F.R.C.R, Dunne, Mary T., M.Sc, Fitzpatrick, David A., F.F.R.R.C.S.I, Finn, Marie A, Cannon, Mairín E., Ph.D, Taylor, Judy C., B.Sc, O'Shea, Carmel M., B.N.S, Buckney, Steven J, Thirion, Pierre G., F.F.R.R.C.S.I
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.09.2011; Elsevier
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - radiotherapy; Aged; Androgen Antagonists - therapeutic use; ANTIGENS; Antineoplastic Agents, Hormonal - therapeutic use; Biochemical failure; Biological and medical sciences; BODY; CLINICAL TRIALS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; Disease-Free Survival; DISEASES; Drug Administration Schedule; Flutamide - therapeutic use; GLANDS; Gynecology. Andrology. Obstetrics; HAZARDS; Hematology, Oncology and Palliative Medicine; HORMONES; Humans; Male; Male genital diseases; MALE GENITALS; Medical sciences; MEDICINE; Middle Aged; Neoadjuvant hormonal therapy; Neoadjuvant Therapy - methods; Neoplasm Staging - methods; NEOPLASMS; Nephrology. Urinary tract diseases; NUCLEAR MEDICINE; ORGANS; PROSTATE; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; RADIOLOGY; RADIOLOGY AND NUCLEAR MEDICINE; RADIOTHERAPY; Radiotherapy, Conformal - methods; Randomized clinical trial; Risk Factors; SKELETON; TESTING; THERAPY; TOMOGRAPHY; Treatment Outcome; Triptorelin Pamoate - therapeutic use; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Randomized clinical trial; Neoadjuvant hormonal therapy; Radiotherapy; Prostate cancer; Biochemical failure; Urinary system disease; Prostate disease; Clinical research; Malignant tumor; Neoadjuvant treatment; Clinical trial; Male genital diseases; Comparative study; Cancer
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2010.04.065

Purpose To examine the long-term outcomes of a randomized trial comparing short (4 months; Arm 1) and long (8 months; Arm 2) neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Methods and Materials Between 1997 and 2001, 276 patients were enrolled and the data from 261 were analyzed. The stratification risk factors were prostate-specific antigen level >20 ng/mL, Gleason score ≥7, and Stage T3 or more. The intermediate-risk stratum had one factor and the high-risk stratum had two or more. Staging was done from the bone scan and computed tomography findings. The primary endpoint was biochemical failure-free survival. Results The median follow-up was 102 months. The overall survival, biochemical failure-free survival. and prostate cancer-specific survival did not differ significantly between the two treatment arms, overall or at 5 years. The cumulative probability of overall survival at 5 years was 90% (range, 87–92%) in Arm 1 and 83% (range, 80–86%) in Arm 2. The biochemical failure-free survival rate at 5 years was 66% (range, 62–71%) in Arm 1 and 63% (range, 58–67%) in Arm 2. Conclusion No statistically significant difference was found in biochemical failure-free survival between 4 months and 8 months of neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.